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Genetic engineering in the mouse has ushered in a new era
of disease modeling that has advanced our understanding of
podocyte injury in the pathogenesis of focal segmental
glomerulosclerosis. Historically, the major animal models of
focal segmental glomerulosclerosis involve direct podocyte
injury (exemplified by toxin models) and indirect podocyte
injury due to adaptive responses (exemplified by renal
ablation models). In both paradigms, recent evidence
indicates that podocyte depletion is a major
pathomechanism mediating proteinuria and
glomerulosclerosis. Podocyte-specific toxin models support
that podocyte loss is sufficient to cause focal segmental
glomerulosclerosis in a dose-dependent manner. Knockout
and transgenic models have provided proof of concept that
mutations in specific podocyte proteins mediate genetic
forms of focal segmental glomerulosclerosis. Transgenic
models of HIV-associated nephropathy have helped to
elucidate the role of direct viral infection and podocyte
expression of viral gene products in the pathogenesis of this
form of collapsing glomerulopathy. Taken together,
emerging data support that injury directed to or inherent
within the podocyte constitutes the critical event in diverse
pathways to glomerulosclerosis.
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This review will focus on podocyte injury models that closely
approximate the human diseases of focal segmental glome-
rulosclerosis (FSGS) and minimal change disease (MCD).
Using a thematic approach, it will highlight major concepts
and advances in our understanding of pathomechanisms,
drawing parallels wherever possible to human disease. The
discussion will not extend to the many other diseases in
which the podocyte is known to be a major participant, such
as membranous glomerulopathy, diabetic nephropathy, and
crescentic glomerulonephritis.
Just a decade ago, our knowledge of podocyte injury in
animal models was rudimentary. We recognized two major
paradigms of irreversible podocyte injury leading to FSGS.
The first is direct podocyte injury due to exposure to such cell
toxins as puromycin aminonucleoside and adriamycin/
doxorubicin.1 These toxic models, which induce podocyte
oxidative stress, fostered the concept of primary podocyte
injury in the pathogenesis of foot process effacement and
glomerulosclerosis. By contrast, renal ablation models
pointed to glomerular hypertension (elevated glomerular
capillary pressures and flow rates) as the primary patho-
physiologic process in the course of adaptive responses to
reduced number of functioning nephrons or other glome-
rular stress, in turn causing secondary podocyte injury.2 These
basic paradigms form the conceptual dichotomy between
‘primary’ and ‘secondary’ (post-adaptive) FSGS. Only in the
past few years has the molecular basis for these pathologic
alterations been elucidated through a greater understanding of
podocyte biology. In particular, the advent of genetic
engineering in the mouse has ushered in a new era in disease
modeling that extends beyond conventional approaches, such
as cell culture and morphologic description. The wealth of
data gleaned from these animal models supports that injury
directed to or originating within the podocyte constitutes the
critical event in diverse pathways to glomerulosclerosis.
ACT 1: SEEING IS BELIEVING: ULTRASTRUCTURAL STUDIES
PROVIDE MECHANISTIC INSIGHTS
Historically, several landmark ultrastructural studies have been
extremely powerful in the elegance and simplicity of their
observations. Initial insights into the podocyte injury in
proteinuric conditions came from meticulous three-dimensional
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ultrastructural observations using scanning electron micro-
scopy. Applying the techniques of sodium hydroxide
maceration to digest the basement membrane components
of the glomerulus and freeze cracking to expose the
undersurface of the podocyte, Inokuchi et al.3 studied the
sequence of podocyte alterations in puromycin nephropathy.
Over the course of 8 days after exposure to puromycin
toxin, the podocytes undergo a distinctive and predictable
change in cell shape.3 The foot processes, which are
analogous to specialized lamellipodia in other biologic
systems, lose their interdigitating tapered appearance as
they become progressively broadened and fanned, incrimi-
nating the actin cytoskeleton in the effacement process.
This simple, but elegant, observation laid the groundwork
for elucidation of specific actin-associated podocyte
proteins that may be operant in foot process maintenance.
It showed that foot process effacement is not a degenerative
change, but rather an active choreographed process in which
reorganization of the actin cytoskeleton is likely to play a
critical role.
A decade later, studies by Reiser et al.4 in a model of
transient proteinuria induced by endotoxin (lipopolysaccharide)
elucidated the nature of this cytoskeletal alteration. Severe
combined immunodeficiency mice exposed to lipopolysac-
charide develop reversible proteinuria and foot process
effacement resembling human MCD. The podocyte injury
in this model is mediated by podocyte upregulation of B7-1
(or CD80), an antigen expressed on B cells and other antigen-
presenting cells that provides costimulatory signal for T cells.
Podocytes are equipped with lipopolysaccharide receptors,
CD14 and toll-like receptor-4. Using cell culture as a
functional assay system, podocytes exposed to lipopolysac-
charide show loss of the typical stress fiber pattern with
development of a dense subcortical ring of actin, leaving the
submembranous space devoid of actin filaments. Clearly
shown in this model is that the in vitro analogue of foot
process effacement is a destabilization of the submembranous
actin cytoskeleton, such that the podocyte is unable to
support process formation.4 This study is also important
because it identified the podocyte as a member of the innate
immune system, able to identify and respond to infectious
pathogenic motifs through toll-like receptor. It is not yet
known whether this signaling network may play a role in
human MCD.
Seminal ultrastructural observations by Nagata and Kriz5
in an ablation model of FSGS showed remarkably different
podocyte alterations. Uninephrectomy in 10-day-old Sprague–
Dawley rats leads to FSGS by 6 months of age. As the tuft
hypertrophies in response to the reduced number of functioning
nephrons, podocyte cell number does not increase, indicating
the inability of podocytes to proliferate in response to the
hypertrophic stimulus. Podocyte cell bodies are forced to stretch
to cover a much larger surface area and serve many more
glomerular capillaries. Cell bodies hypertrophy and become
attenuated into cytoplasmic sheets as their primary processes
thin out and extend to remote capillaries. Filtrate is now
delivered into the subcell-body space, causing bulging of the
cytoplasmic sheets and formation of pseudocysts, under which
foot processes are largely preserved. In this model, the
formation of denuded patches of GBM owing to podocyte
detachment and the apposition of distended podocyte cell
bodies to Bowman’s capsule form the nidus for lesions of
segmental sclerosis to develop. Interestingly, the segmental
lesions in this model were typically perihilar, as occurs in
human post-adaptive FSGS.6 This visually compelling model
was extremely important in formulating the concept that
podocyte insufficiency resulting from maladaptive glomerular
responses is the critical precursor to irreversible structural
lesions. This sequence of events forms the basis of our current
structural view of post-adaptive (secondary) FSGS.
ACT 2: GOING, GOING, GONEy THE ROLE OF PODOCYTE
DEPLETION
In both toxic and adaptive models of FSGS, a central role for
podocyte loss has been proposed. Podocyte depletion has
been identified in many human glomerular diseases, includ-
ing diabetic nephropathy, FSGS, and IgA nephropathy.7,8 In
human disease, podocytes can be detected in the urine and
the reduction in podocyte cell number correlates with the
degree of proteinuria and severity of sclerosis.9
This mechanism has been validated in several ingenious
models of targeted podocyte cell death.10–12 These models ask
the questions: Can cell injury directed specifically and
exclusively to the podocyte result in glomerulosclerosis? Is
podocyte depletion sufficient to cause FSGS? Using a
transgenic rat strain in which the human diphtheria toxin
(DT) receptor is specifically expressed in podocytes driven
by the podocin promoter, Wiggins and co-workers were
able to produce different stages of glomerular injury
depending on the percentage of podocytes depleted after
injection of DT, consistent with a dose response.10 The
investigators chose the rat because glomerulosclerosis in this
species resembles more closely that seen in man. They
selected DT because the DT receptor homologue in rat fails to
detect DT. Expression of the human DT receptor, HB-EGF-
like growth factor, on the surface of rat podocytes allows the
toxin to be internalized by receptor-mediated endocytosis,
resulting in inhibition of protein synthesis by ribosylation of
the polypeptide chain elongation factor 2. A high dose of DT
causes massive proteinuria by day 2 followed by FSGS lesions
by day 28. Up to 20% loss of podocytes produced transient
proteinuria with mild mesangial expansion and no effect on
renal function. A greater (21–40%) loss of podocytes
produced synechiae and FSGS lesions with sustained mild
proteinuria and normal renal function. Over 40% podocyte
depletion produced the full-blown picture of focal segmental
and global glomerulosclerosis with high-grade proteinuria
and reduced renal function. Thus, in this model, the degree
of podocyte depletion directly correlated with structural and
functional measures of glomerular injury. Importantly, there
was a threshold effect above which FSGS lesions were
produced.
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In another podocyte toxin model, Ichikawa and co-
workers engineered a transgenic mouse model of glomerulo-
sclerosis by selectively expressing human CD25 (human IL2
receptor light chain) in podocytes under control of the
nephrin promoter.11,12 Injection of anti-Tac (Fv)-PE38
(LMB2) immunotoxin induced progressive proteinuria and
glomerulosclerosis in a dose-dependent manner. The toxin
consists of a fusion of pseudomonas exotoxin A with the
variable region of anti-CD25 antibody, directing toxin
specifically to the podocytes expressing CD25. Like DT, the
pseudomonas exotoxin A causes cell death by ribosylation of
elongation factor 2 and inhibition of protein synthesis. By
permanently labeling the podocyte lineage with lacZ, the
investigators could follow their fate over time. This lineage-
specific tag was retained despite severe dysregulation of the
podocytes and loss of mature podocyte markers such as
synaptopodin. The number of lacZ-stained podocytes
progressively declined as parietal epithelial cells proliferated
to cover the denuded tuft, resembling collapsing FSGS. These
studies demonstrate the critical role of podocyte depletion in
the process of glomerular sclerosis. They also suggest that the
mass of glomerular epithelial cells in collapsing FSGS is
comprised largely of proliferating parietal epithelial cells.
Next, the investigators produced a chimeric model in
which only some of the podocytes expressed the CD25
receptor.13 Surprisingly, administration of immunotoxin
resulted in the same degree of glomerulosclerosis as in the
transgenic model where every podocyte expresses the
receptor. This study shows that if the initial insult is of
sufficient impact, there may be spreading of injury to
adjacent podocytes that had escaped the original insult,
producing a kind of domino effect. Injury may spread from
one podocyte to its neighbor until the entire glomerular
lobule is captured. Such a process of local spreading could
explain what every pathologist has appreciated—the exquisite
segmentality of the sclerotic lesions. Small losses of podocytes
may be contained by synechiae to Bowman’s capsule.
However, critical losses of a larger number of podocytes
may spread to involve an entire segment, as suggested by the
thresholds demonstrated in the DT model.10 A podocyte
sends out foot processes to interdigitate only with other
podocytes within its own glomerular lobule or segment,
which is a subunit of glomerular capillaries that is formed by
a major branch of the incoming afferent arteriole. Each
glomerulus contains from 6 to 8 individual lobules formed by
dichotomous branchings of the afferent arteriole. It is
tempting to speculate that if a healthy podocyte loses its
interdigitating partner, it in turn can succumb, either because
of toxic substances secreted in a paracrine or autocrine
manner (such as TGFb or AII) or reduction in survival
factors (such as vascular endothelial growth factor or nephrin
signaling).13 Cell signaling through an intact slit diaphragm is
likely to be a critical process in podocyte survival. Chimeric
toxin models such as this should provide an experimental
construct to explore these potential mediators.
ACT 3: PROOF OF CONCEPT: ANIMAL MODELS AND THE
GENETIC BASIS OF FSGS
Great advances have been made in our understanding of the
genetic basis for FSGS. A number of critical podocyte
proteins have been identified to be mutated or deficient in
human forms of congenital nephrotic syndrome or inherited
FSGS14–27 (Table 1). Most of these proteins, including
nephrin, podocin, a-actinin-4, and TRPC6, were identified
first by positional cloning in affected families. Others, such as
CD2AP, were identified serendipitously in an experimental
Table 1 | Podocyte genes mutated in human forms of FSGS or congenital nephrotic syndrome
Human gene products Gene Inheritance Chromosome
Slit diaphragm proteins
Nephrin* NPHS1 AR (Finnish CNS) 19q13.1
Podocin* NPHS2 AR 1q25–31
CD2-associated protein* CD2AP AD 6p12
Transient receptor potential cation 6 TRPC6 AD 11q21–22
Cytosolic proteins
a-Actinin-4* ACTN4 AD 19q13
Phospholipase C e1 PLCE1 AR 10q23–24
Basal membrane proteins
Laminin-b2* LAMB2 AR (Pierson syndrome) 3p21
b-4-integrin ITGB4 AR (epidermolysis bullosa) 17q11
Tetraspanin CD151* CD151 AR (epidermolysis bullosa/deafness) 11p15
Nuclear proteins
Wilm’s tumor 1* WT1 AD (DMS, Frasier syndrome) 11p13
Chromatin-bundling protein SMARCAL1 AD (Schimke syndrome) 2q34–36
Mitochondrial products
Mitochondrial tRNAleu mtDNA-A3243G Maternal mtDNA
AD, autosomal dominant; AR, autosomal recessive; CNS, congenital nephrotic syndrome; DMS, diffuse mesangial sclerosis.
*Validated in animal models.
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context while studying other disease systems. The critical
role of many of these proteins in the mediation of FSGS
was later validated in experimental models, including
knockout models and transgenic models expressing mutant
proteins28–38 (Table 1, marked with asterisk). The animal
models provided proof of concept that deletion of a
particular gene was sufficient to cause proteinuria or FSGS.
A number of other podocyte proteins produce FSGS in
null mice or conditional knockouts, although a role in
human disease has not yet been identified39–44 (Table 2).
The responsible genes encode proteins that are located in
various subcellular domains of the podocyte, including
membrane-associated (slit diaphragm, basal membrane),
nuclear (transcription factors and chromatin bundling
proteins), and cytosolic (associated with the actin cytos-
keleton or cell energetics).
Most common among these are genetic defects in slit
diaphragm proteins. Autosomal recessive forms (such as
mutations in nephrin or podocin) tend to manifest early in
life, whereas autosomal dominant forms (such as mutations
in a-actinin-4 or TRPC6) typically develop disease pheno-
types in adulthood. The corresponding animal models
provide insight into inherent defects within the podocyte
that can initiate disease and which downstream cellular
pathways are impacted. Genetic predisposition may be
modulated or compounded by environmental or other
insults allowing multiple ‘hits’ to accumulate before clinical
disease is manifest, particularly in adult-onset forms. This
concept would explain the incomplete penetrance observed
both in a-actinin-4-deficient mice and in mice transgenic for
podocyte-specific expression of mutant a-actinin-4.33,34
A unifying concept in all these models is the central role of
the actin cytoskeleton to coordinate cell signaling from the
various membrane compartments. Interference with these
signaling networks may promote the stereotypic response of
foot process effacement common to all these conditions.45
This hypothesis is supported by the evidence that the slit
diaphragm is not simply an inert mechanical support. It is
also a mechanosensor that serves as a platform for initiation
of signal transduction.46 Nephrin and Neph1 cytoplasmic
tails contain tyrosine phosphorylation sites that may serve as
docking sites for adaptor proteins to initiate signal transduc-
tion events that regulate complex biologic processes, such as
cell survival, polarity, and actin remodeling, any or all of
which could be critical to the FSGS disease phenotype.46
ACT 4: MORE IS NOT NECESSARILY BETTER: PODOCYTE
DYSREGULATION AND GLOMERULAR EPITHELIAL CELL
PROLIFERATION IN COLLAPSING FSGS
The mature podocyte is a post-mitotic cell. Podocytes can
undergo DNA synthesis to a limited degree but do not
proliferate, because they arrest in the G2/M phase of the cell
cycle.47 Findings in human collapsing FSGS suggest that
podocytes may exhibit rare replicative capacity under selected
conditions, producing the glomerular pseudocrescents typi-
cal of this variant.48 This has been difficult to prove in man
and in animal models without lineage-specific markers, and
there is increasing evidence that parietal epithelial cells
contribute importantly to the glomerular epithelial cell
proliferation.49 In collapsing FSGS, the podocytes down-
regulate their mature podocyte markers (WT-1, synaptopo-
din, podocalyxin, GLEPP-1), express KI-67, and may enter
the cell cycle.48,50 A similar dysregulated podocyte phenotype
has been identified in primary collapsing glomerulopathy and
human HIV-associated nephropathy (HIVAN), as well as an
HIV transgenic model.48,51 A decrease in the cyclin-
dependent kinase inhibitors, p27 and p57, and increase in
cyclin D1 underlie the proliferative phenotype.52,53
Evidence in human HIVAN supports a role for direct viral
infection of renal parenchymal cells, including the podocyte.
Bruggeman et al. detected HIV-1 in renal epithelial cells of
patients with HIVAN both by RNA in situ hybridization using
riboprobes specific for both the nef and gag genes and by
DNA in situ hybridization.54 Virus was identified in renal
tubular cells, often involving many contiguous cells in
individual tubular profiles, as well as in podocytes, parietal
epithelial cells, and some interstitial leukocytes.54 In one
illustrative case treated with highly active antiretroviral
therapy, virus persisted in the tubular epithelium as
determined by RNA in situ hybridization, even after viral
load in the peripheral blood had become undetectable and
renal histology had improved.55 The ability of the kidney to
serve as a reservoir for HIV-1 was later confirmed by Marras
et al.56 using laser capture microdissection to characterize the
HIV-1 quasispecies present in tubular epithelium. Compar-
ison of the envelope sequences from renal tubular epithelial
cells and peripheral blood leukocytes in individual patients
showed variations in the HIV-1 envelope sequences in
tubular epithelium compared to blood. By phylogenetic
analysis, the HIV quasispecies detected in kidney comprised
distinct subclusters within the radiations of PBMC, indicat-
ing that the kidney is able to support viral replication and
quasispecies evolution as a separate compartment.
Several animal models of HIVAN have been exploited to
provide insights into disease pathogenesis. One of the first
models, Tg26, was established in transgenic mice containing
a replication-defective HIV-1 construct that lacks a 3.1 kb
fragment spanning the gag and pol genes and is expressed
under the control of the endogenous long terminal repeat
Table 2 | Mouse gene mutants causing FSGS
Role in human disease unknown
Slit diaphragm proteins
Neph1
Fyn
FAT1
Actin-associated proteins
Nck 1/2
Basal membrane proteins
Integrin-linked kinase
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viral promoter.57 In this model, which closely recapitulates
the morphologic features of the human disease, viral
transgene is expressed in glomerular and tubular epithelial
cells.58 Cross-transplantation of kidneys between Tg26 and
WT mice showed that renal transgene expression was
required for the development of nephropathy and argued
against a role for circulating viral proteins or dysregulated
cytokine milieu.57 In the Tg26 model, inhibition of renal
epithelial proliferation using a cyclin-dependent kinase 2
inhibitor reduced proteinuria and glomerulosclerosis, sug-
gesting an important role for dysregulated cell proliferation
in disease pathogenesis.59
Which HIV genes are necessary and sufficient to produce
the HIVAN renal phenotype? The original Tg26 model
indicates that gag (which encodes for HIV nucleocapsid and
core proteins) and pol (which encodes the enzymes reverse
transcriptase, ribonuclease, and integrase) are not required.
But which of the other regulatory and accessory genes is (are)
needed? Hanna et al.60 generated several different transgenic
lines with mutations in one or more of the HIV genes and
found that nef was necessary and sufficient to produce the
renal phenotype. In vitro studies in cultured podocytes
suggest that nef-induced activation of Stat3 and Ras-MAPK1,
2 via Src-dependent pathways is responsible for podocyte
proliferation and dedifferentiation.61
Investigators then asked whether podocyte-restricted
expression of HIV genes can recapitulate the entire renal
phenotype. Transgenic expression of the nonstructural HIV-1
genes, including vif, vpr, nef, and spliced forms of tat and rev
selectively in podocytes under the nephrin promoter in mice
with FVB/N genetic background, results in podocyte injury,
glomerulosclerosis, and tubular microcyst formation.62
Podocyte-specific expression of nef under control of the
podocin promoter produced a dedifferentiated podocyte
phenotype in vivo, but the mice failed to develop proteinuria
or FSGS lesions.63 This suggested that podocyte expression of
nef alone is not sufficient to produce the full HIVAN
phenotype in vivo, and one or more genes may be required.
Podocyte-specific expression of nef and vpr in a double-
transgenic murine model replicated the severe morphologic
and functional features of human HIVAN, indicating an
important synergistic interaction.64 Nef induces signaling
networks in podocytes that regulate proliferation, dediffer-
entiation, stress fiber maintenance, and formation of
lamellipodia. Vpr, which is involved in the intracellular
transport of HIV-1 preintegration complex, also affects
diverse cell functions, such as G2 cell cycle arrest, regulation
of apoptosis, transcriptional activation, and cytoskeletal
dynamics. Together, these two genes could dysregulate critical
podocyte cellular functions.
In HIVAN and idiopathic collapsing glomerulopathy, the
proliferating podocytes have an undifferentiated phenotype,
leading to functional podocyte insufficiency, defective
podocyte adhesion, and shedding of podocytes into the
urine. Over the long-term, collapsing glomerulopathy is
likely to lead to progressive podocyte depletion, as in other
models of FSGS. A controversial issue is whether podocytes
might be capable of regeneration, apart from the prolifera-
tion of dysregulated podocytes observed in collapsing FSGS.
The ability of podocytes to be replenished by bone marrow-
derived stem cells has been demonstrated in COL4A3
knockout mice with Alport-like disease, leading to improved
glomerular architecture and reduction in proteinuria.65 As
yet, the potential for similar recruitment of progenitor cells as
visceral epithelial cells in damaged glomeruli of human FSGS
remains unknown.
ACT 5: THE MISSING LINK: HOW IRREVERSIBLE FOOT
PROCESS EFFACEMENT AND PODOCYTE LOSS PROMOTE
GLOMERULOSCLEROSIS
Foot process effacement is a hallmark of glomerular injury
leading to proteinuria in the vast majority of human
glomerulopathies and animal models of proteinuric glomer-
ular disease, with rare exceptions.66 Conventional wisdom
suggests that foot process effacement, if reversed, can lead to
restoration of glomerular architecture, as typically observed
in steroid-responsive MCD. The failure of reparative
mechanisms promotes persistent proteinuria and the devel-
opment of glomerulosclerosis (Figure 1). What animal
models have failed to identify is the point of no return, the
critical level of cell stress at which podocyte structural
alterations inherent in the effacement process activate
pathways to irreversible podocyte injury. How does persistent
effacement itself interfere with podocyte regulatory processes
to promote podocyte detachment, apoptosis, and depletion?
Apart from the obvious structural defect, why does podocyte
loss necessarily eventuate in glomerulosclerosis? Our under-
standing of these missing links could hold the key for
successful treatment of FSGS, before irreversible structural
lesions ensue.
Evidence from animal models suggests that critical
perturbations in the balance between proapoptotic and
antiapoptotic factors promote podocyte depletion and
Injury
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Intact foot processes
GBM
Filtration slit 
diaphragm
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Effacement
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Figure 1 | The relationship of podocyte injury to foot process
effacement and glomerulosclerosis.
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progressive glomerulosclerosis (reviewed by Shankland47).
Many of the proapoptotic podocyte factors (such as AII and
TGFb) also possess prosclerotic properties, providing a
possible synergistic link to sclerosis.
The TGFb1 transgenic mouse is a particularly valuable
model that has shed mechanistic insights into the inter-
relationship between podocyte apoptosis and glomerulo-
sclerosis.67 Transgenic mice overexpressing TGFb1 (under
control of the albumin promoter leading to increased hepatic
production) develop podocyte apoptosis and glomerulo-
sclerosis concurrently. In this model, podocyte apoptosis
occurs both through upregulation of podocyte Smad7 (which
inhibits cell survival factor NF-kB) and classic TGFb1-
inducible effector caspases. Thus, through a common
mediator, podocyte apoptosis and profibrotic cytokine path-
ways converge toward a sclerotic glomerular phenotype.
A critical factor in steroid-resistant FSGS that distin-
guishes it from MCD is the irreversibility of proteinuria and
foot process effacement. There is emerging evidence that
unremitting proteinuria itself can augment podocyte injury,
perhaps tipping the balance toward podocyte apoptosis or
detachment in various disease settings. For example, excess
podocyte protein trafficking has been shown in a renal
ablation model to upregulate podocyte TGFb in vivo and in
vitro.68 Excessive protein accumulation in podocytes pro-
motes ER stress, cytoskeletal reorganization, and podocyte
dedifferentiation.69 Induction of lysosomal cathepsin L in
podocytes following lipopolysaccharide exposure cleaves
substrate dynamin, an actin-associated protein required for
cytoskeletal maintenance, resulting in foot process effacement
and proteinuria.70 In the urinary space of the proteinuric
glomerulus, the convergence of protein-rich filtrate toward
the tubular pole could increase shear stress on the podocyte’s
apical surface, leading to podocyte injury and apoptosis.71 In
the effaced mode, without their normal foot process anchors,
podocytes may be less resistant to physiologic levels of shear
stress arising from normal filtration forces because of
weakened adhesion to extracellular matrix, allowing the cells
to detach and be shed into the urinary space. This shedding
of podocytes is observed frequently in renal biopsies of
patients with various forms of FSGS. Once podocytes are lost,
the increased mechanical stretch on residual podocytes could
promote their hypertrophy and apoptosis.72 It is possible that
foot process effacement itself reduces nephrin signaling (an
antiapoptotic, prosurvival factor) due to resulting structural
perturbations in the filtration slit diaphragm, producing a
vicious cycle of podocyte injury (Figure 1).
Effective therapeutic regimens for MCD and FSGS
typically include steroids and ACE inhibitors or ARB, all of
which exert direct effects on podocytes in addition to their
systemic effects. Glucocorticoid protects podocytes from
apoptosis, as demonstrated in models of puromycin-induced
podocyte injury.73 Inhibitors of angiotensin II also reduce
podocyte hypertrophy and possess antiapoptotic properties.
A transgenic rat model with podocyte-specific overexpression
of the angiotensin II type 1 receptor, leading to increased
AT1-mediated signaling selectively in the podocyte, develops
proteinuria and FSGS, independent of systemic hyper-
tension.74 Podocytes express erythropoietin receptors, which
may prove to be another important podocyte survival factor.
Treatment with the darbepoetin-a has been shown to protect
podocytes from apoptosis in puromycin nephropathy,
leading to reduced proteinuria and glomerulosclerosis.75
These findings suggest a possible future role for erythro-
poiesis stimulating proteins and other podocyte survival
factors in the treatment of progressive glomerular disease.
In summary, injurious mechanisms put into play by foot
process effacement and unremitting proteinuria may be
important mediators of cumulative, eventually irreversible
podocyte injury, leading inexorably to glomerulosclerosis.
Future experimental models should aim to dissect these
effects. The accrued impact of irreversible foot process
effacement over time could explain the observation by
pathologists that lesions of FSGS commonly supervene on
many forms of chronic glomerular disease with unremitting
proteinuria in such diverse contexts as membranous
glomerulopathy, diabetic glomerulosclerosis, and prolifera-
tive glomerulonephritis. Based on emerging evidence from
animal models and observations in humans, it is likely that
podocyte loss will prove to be the common pathway to
glomerulosclerosis in many glomerular diseases.
REFERENCES
1. Ryan GB, Karnovsky MJ. An ultrastructural study of the mechanisms of
proteinuria in aminonucleoside nephrosis. Kidney Int 1975; 8: 219–232.
2. Olson JL, Hostetter TH, Rennke HG et al. Altered glomerular
permselectivity and progressive sclerosis following extreme ablation of
renal mass. Kidney Int 1982; 22: 112–126.
3. Inokuchi S, Shirato I, Kobayashi N et al. Re-evaluation of foot process
effacement in acute puromycin aminonucleoside nephrosis. Kidney Int
1996; 50: 1278–1287.
4. Reiser J, von Gersdorff G, Loos M et al. Induction of B7-1 in podocytes
is associated with nephrotic syndrome. J Clin Invest 2004; 10:
1390–1397.
5. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young
rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney
Int 1992; 42: 148–160.
6. D’Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of
focal segmental glomerulosclerosis: a working proposal. Am J Kid Dis
2004; 43: 368–382.
7. Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term
urinary albumin excretion in Pima Indians with type II diabetes and
microalbuminuria. Diabetologia 1999; 42: 1341–1344.
8. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease
severity in IgA nephropathy. Kidney Int 2002; 61: 1475–1485.
9. Hara M, Yanagihara T, Kihara I. Urinary podocytes in primary focal
segmental glomerulosclerosis. Nephron 2001; 89: 342–347.
10. Wharram BL, Goyal M, Wiggins J et al. Podocyte depletion causes
glomerulosclerosis: diptheria toxin-induced podocyte depletion in rats
expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol
2005; 16: 2941–2952.
11. Matsusaka T, Xin J, Niwa S et al. Genetic engineering of glomerular
sclerosis in the mouse via control of onset and severity of podocyte
specific injury. J Am Soc Nephrol 2005; 16: 1013–1023.
12. Asano T, Niimura F, Pastan I et al. Permanent genetic tagging of
podocytes: fate of injured podocytes in a mouse model of glomerular
sclerosis. J Am Soc Nephrol 2005; 16: 2257–2262.
13. Ichikawa I, Ma J, Motojima M, Matsusaka T. Podocyte damage
damages podocytes: autonomous vicious cycle that drives local
spread of glomerular sclerosis. Curr Opin Nephrol Hypertens 2005; 14:
205–210.
404 Kidney International (2008) 73, 399–406
m i n i r e v i e w VD D’Agati: Podocyte animal models
14. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria
syndromes and mechanisms of proteinuria. N Eng J Med 2006; 354:
1387–1401.
15. Kestila M, Lenkkeri U, Mannikko M et al. Positionally cloned gene for a
novel glomerular protein—nephrin—is mutated in congenital nephrotic
syndrome. Mol Cell 1998; 1: 575–582.
16. Boute N, Gribouval O, Roselli S et al. NPHS2, encoding the glomerular
protein podocin, is mutated in autosomal recessive steroid-resistant
nephrotic syndrome. Nat Genet 2000; 24: 349–354.
17. Koziell A, Grech V, Hussain S et al. Genotype/phenotype correlations of
NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a
functional inter-relationship in glomerular filtration. Hum Mol Genet 2002;
11: 379–388.
18. Kim JM, Wu H, Green G et al. CD2-associated protein haploinsufficiency is
linked to glomerular disease susceptibility. Science 2003; 300: 1298–1300.
19. Winn MP, Conlon PJ, Lynn KL et al. A mutation in the TRPC6 cation
channel causes familial focal segmental glomerulosclerosis. Science 2005;
308: 1801–1804.
20. Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding
a-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet
2000; 24: 251–256.
21. Hinkes B, Wiggins RC, Gbadegesin R et al. Positional cloning uncovers
mutations in PLCe1 responsible for a nephrotic syndrome variant that
may be reversible. Nat Genet 2006; 38: 1397–1405.
22. Zenker M, Aigner T, Wendler O et al. Human laminin beta2 deficiency
causes congenital nephrosis with mesangial sclerosis and distinct eye
abnormalities. Hum Mol Genet 2004; 13: 2625–2632.
23. Kambham N, Tanji N, Seigle RL et al. Congenital focal segmental
glomerulosclerosis associated with b4 integrin mutation and
epidermolysis bullosa. Am J Kid Dis 2000; 36: 190–196.
24. Karamatic Crew V, Burton N, Kagan A et al. CD151, the first member of
the tetraspanin (TM4) superfamily detected on erythrocytes, is essential
for the correct assembly of human basement membranes in kidney and
skin. Blood 2004; 104: 2217–2222.
25. Denamur E, Bocquet N, Mougenot B et al. Mother-to-child transmitted
WT1 splice-site mutation is responsible for distinct glomerular diseases.
J Am Soc Nephrol 1999; 10: 2219–2223.
26. Lucke T, Billing H, Sloan EA et al. Schimke-immuno-osseous dysplasia:
new mutation with weak genotype–phenotype correlation in siblings. Am
J Med Genet A 2005; 135: 202–205.
27. Guery B, Choukroun G, Noel LH et al. The spectrum of systemic
involvement in adults presenting with renal lesion and tRNA (Leu) gene
mutation. J Am Soc Nephrol 2003; 14: 2099–2108.
28. Putaala H, Soininen R, Kilpelainen P et al. The murine nephrin gene is
specifically expressed in kidney, brain and pancreas: inactivation of the
gene leads to massive proteinuria and neonatatal death. Hum Mol Genet
2001; 10: 1–8.
29. Roselli S, Heidet L, Sich M et al. Early glomerular filtration defect and
severe renal disease in podocin-deficient mice. Mol Cell Biol 2004; 24:
550–560.
30. Shih NY, Li J, Karpitskii V et al. Congenital nephrotic syndrome in mice
lacking CD2-associated protein. Science 1999; 286: 312–315.
31. Michaud JL, Lemieux LI, Dube M et al. Focal and segmental
glomerulosclerosis in mice with podocyte-specific expression of mutant
alpha-actinin-4. J Am Soc Nephrol 2003; 14: 1200–1211.
32. Kos CH, Le TC, Sinha S et al. Mice deficient in alpha-actinin-4 have severe
glomerular disease. J Clin Invest 2003; 111: 1683–1690.
33. Yao J, Le T, Kos C et al. Alpha-actinin-4 mediated FSGS: an inherited
kidney disease caused by an aggregated and rapidly degraded
cytoskeletal protein. PLoS Biology 2004; 2: 0787–0794.
34. Michaud J, Chaisson K, Parks R, Kennedy C. FSGS-associated alpha-
actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int
2006; 70: 1054–1061.
35. Kreidberg JA, Donovan MJ, Goldstein SL et al. Alpha 3 beta 1 integrin has
a crucial role in kidney and lung organogenesis. Development 1996; 122:
3537–3547.
36. Jarad G, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes
podocyte abnormalities in Lamb2/ mice, implicating the glomerular
basement membrane as an albumin barrier. J Clin Invest 2006; 116:
2272–2279.
37. Sachs N, Kreft M, van den Bergh Weerman M et al. Kidney failure in mice
lacking the tetraspanin CD151. J Cell Biol 2006; 175: 33–39.
38. Guo JK, Menke AL, Gubler MC et al. WT1 is a key regulator of
podocyte function: reduced expression levels cause crescentic
glomerulonephritis and mesangial sclerosis. Hum Mol Genet 2002; 11:
651–659.
39. Donoviel DB, Freed DD, Vogel H et al. Proteinuria and perinatal lethality in
mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell
Biol 2001; 21: 4829–4836.
40. Ciani L, Patel A, Allen ND, ffrench-Constant C. Mice lacking the giant
protocadherin mFAT1 exhibit renal slit junction abnormalities and a
partially penetrant cyclopia and anophthalmia phenotype. Mol Cell Biol
2003; 23: 3575–3582.
41. Huber TB, Kwoh C, Wu H et al. Bigenic mouse models of focal segmental
glomerulosclerosis involving pairwise interaction of CD2AP, Fyn and
synaptopodin. J Clin Invest 2006; 116: 1337–1345.
42. Jones N, Blasutig IM, Eremina V et al. Nck adaptor proteins link nephrin to
the actin cytoskeleton of kidney podocytes. Nature 2006; 440: 818–823.
43. El-Aouni C, Herbach N, Blattner S et al. Podocyte-specific deletion of
integrin-linked kinase results in severe glomerular basement membrane
alterations and progressive glomerulosclerosis. J Am Soc Nephrol 2006;
17: 1334–1344.
44. Dai C, Stolz D, Bastacky S et al. Essential role of integrin-linked kinase in
podocyte biology: bridging the integrin and slit diaphragm signaling.
J Am Soc Nephrol 2006; 17: 2164–2175.
45. Kerjaschki D. Caught flat-footed: podocyte damage and the molecular
bases of focal glomerulosclerosis. J Clin Invest 2001; 108: 1583–1587.
46. Benzing T. Signaling at the slit diaphragm. J Am Soc Nephrol 2004; 15:
1382–1391.
47. Shankland SJ. The podocyte’s response to injury: role in proteinuria and
glomerulosclerosis. Kidney Int 2006; 69: 2131–2147.
48. Barisoni L, Kriz W, Mundel P, D’Agati V. The dysregulated podocyte
phenotype; a novel concept in the pathogenesis of collapsing idiopathic
focal segmental glomerulosclerosis and HIV-associated nephropathy.
J Am Soc Nephrol 1999; 10: 51–61.
49. Dijkman HB, Weening JJ, Smeets B et al. Proliferating cells in HIV and
pamidronate-associated collapsing focal segmental glomerulosclerosis
are parietal epithelial cells. Kidney Int 2006; 70: 338–344.
50. Bariety J, Bruneval P, Hill et al. Post-transplantation relapse of FSGS is
characterized by glomerular epithelial cell transdifferentiation. J Am Soc
Nephrol 2001; 12: 261–274.
51. Barisoni L, Bruggeman LA, Mundel P et al. HIV-1 induces renal epithelial
dedifferentiation in a transgenic model of HIV-associated nephropathy.
Kidney Int 2000; 58: 173–181.
52. Shankland SJ, Eitner F, Hudkins KL et al. Differential expression of
cyclin-dependent kinase inhibitors in human glomerular disease: role in
podocyte proliferation and maturation. Kidney Int 2000; 58: 674–683.
53. Barisoni L, Mokrzycki M, Sablay L et al. Podocyte cell cycle regulation and
proliferation in collapsing glomerulopathies. Kidney Int 2000; 58: 137–143.
54. Bruggeman LA, Ross MD, Tanji N et al. Renal epithelium is a previously
unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000; 11:
2079–2087.
55. Winston JA, Bruggeman LA, Ross MD et al. Nephropathy and
establishment of a renal reservoir of HIV type 1 during primary infection.
N Engl J Med 2001; 344: 1979–1984.
56. Marras D, Bruggeman LA, Gao F et al. Replication and
compartmentalization of HIV-1 in kidney epithelium of patients with
HIV-associated nephropathy. Nat Med 2002; 8: 522–526.
57. Kopp JB, Klotman ME, Adler SH et al. Progressive glomerulosclerosis and
enhanced renal accumulation of basement membrane components in
mice transgenic for human immunodeficiency virus type 1 genes.
Proc Natl Acad Sci USA 1992; 89: 1577–1581.
58. Bruggeman LA, Dikman S, Meng C et al. Nephropathy in human
immunodeficiency virus-1 transgenic mice is due to renal transgene
expression. J Clin Invest 1997; 100: 84–92.
59. Gherardi D, D’Agati V, Chu TH et al. Reversal of collapsing
glomerulopathy in mice with the cyclin-dependent kinase inhibitor
CYC202. J Am Soc Nephrol 2004; 15: 1212–1222.
60. Hanna Z, Weng X, Kay DG et al. The pathogenicity of human
immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is
abolished by mutation of its SH3-binding domain, and disease
development is delayed in the absence of Hck. J Virol 2001; 75:
9378–9392.
61. He JC, Husain M, Sunamoto M et al. Nef stimulates proliferation of
glomerular podocytes through activation of Src-dependent Stat3 and
MAPK1,2 pathways. J Clin Invest 2004; 114: 643–651.
62. Zhong J, Zuo Y, Ma J et al. Expression of HIV-1 genes in podocytes alone
can lead to the full spectrum of HIV-1 associated nephropathy. Kidney Int
2005; 68: 1048–1060.
63. Husain M, D’Agati VD, He JC et al. HIV-1 nef induces dedifferentiation of
podocytes in vivo: a characteristic feature of HIVAN. AIDS 2005; 19:
1975–1980.
Kidney International (2008) 73, 399–406 405
VD D’Agati: Podocyte animal models m i n i r e v i e w
64. Zuo Y, Matsusaka T, Zhong J et al. HIV-1 genes synergistically damage
podocytes, leading to glomerulosclerosis. J Am Soc Nephrol 2006; 17:
2832–2843.
65. Sugimoto H, Mundel TM, Sund M et al. Bone marrow-derived stem cells
repair basement membrane collagen defects and reverse genetic kidney
disease. Proc Natl Acad Sci USA 2006; 103: 7321–7326.
66. Kalluri R. Proteinuria with and without renal glomerular podocyte
effacement. J Am Soc Nephrol 2006; 17: 2383–2389.
67. Schiffer M, Bitzer M, Roberts ISD et al. Apoptosis in podocytes induced by
TGFb and Smad7. J Clin Invest 2001; 108: 807–816.
68. Abbate M, Zoja C, Morigi M et al. Transforming growth factor B1 is up-
regulated by podocytes in response to excess intraglomerular passage of
proteins. Am J Pathol 2002; 161: 2179–2193.
69. Inagi R, Nangaku M, Onogi H et al. Involvement of endoplasmic reticulum
(ER) stress in podocyte injury induced by excessive protein accumulation.
J Am Soc Nephrol 2005; 68: 2639–2650.
70. Sever S, Altintas MM, Nankoe SR et al. Proteolytic processing of dynamin
by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease.
J Clin Invest 2007; 117: 2095–2104.
71. Friedrich C, Endlich N, Kriz W, Endlich K. Podocytes are sensitive to fluid
shear stress in vitro. Am J Physiol Renal Physiol 2006; 291: F856–F865.
72. Durvasula RV, Petermann AT, Kiromura K et al. Activation of a local tissue
angiotensin system in podocytes by mechanical strain. Kidney Int 2004;
65: 30–39.
73. Wada T, Pippin JW, Marshall CB et al. Dexamethasone prevents podocyte
apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2
related family proteins. J Am Soc Nephrol 2005; 16: 2615–2625.
74. Hoffmann S, Podlich D, Haehnel B et al. Angiotensin II type 1 receptor
overexpression in podocytes induces glomerulosclerosis in transgenic
rats. J Am Soc Nephrol 2004; 15: 1475–1487.
75. Logar CM, Brinkkoetter PT, Krofft RD et al. Darbepoetin alfa protects
podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72:
489–498.
406 Kidney International (2008) 73, 399–406
m i n i r e v i e w VD D’Agati: Podocyte animal models
